.hidden: {display:none;}; .visible: {display:block;}; Federal Government Relations - Health & Life Sciences - FaegreBD Consulting
SEARCH

Contact

David R. Zook[email protected]T:+1 202 589 2809

Health & Biosciences

 Academic Medicine Rare Disease Expertise Venture Philanthropy FDA Regulatory Affairs & Product Safety Federal Government Relations - Health & Life Sciences Health Economics Media Relations - Health & Life Sciences Public Health & Science Policy Reimbursement Affairs State Government Relations - Health & Life Sciences

Federal Government Relations - Health & Life Sciences

Press Releases

TitleDate
Lauren Bloch Brings Coalition, Project Management to Health & Biosciences Team 24 September 2015
Health Markets & Reimbursement Policy Expert Bruce Quinn, M.D., Ph.D. Joins FaegreBD Consulting 20 July 2015
Kevin Brennan Joins FaegreBD Consulting's Health & Biosciences Team 04 August 2014
Allison Durham Joins Health & Biosciences Group at FaegreBD Consulting 31 October 2012

Published Articles

TitleDate
What Does the Future Hold for Patient-Focused Drug Development? 08 October 2015
Narrow Network Health Plans: New Approaches to Regulating Adequacy and Transparency 08 October 2015
After King v. Burwell, Viable Exchanges are ACA's Next Challenge 05 June 2015
Can Congress Coalesce Around The 21st Century Cures Bill? 06 February 2015
Are Brighter Days Ahead for Patient Advocates in Washington? 18 September 2014

Media Mentions

TitleDate
Federal Funding Shortfalls Push Some Affordable Care Act ‘Co-Ops' Over the Ledge, Mike Adelberg Tells The Hill 20 October 2015
Health Insurers Stuck With Bill as CMS Falls Short on Risk-Corridor Payments 14 October 2015
GAO Calls for More Federal Scrutiny of Network Adequacy in Medicare Advantage Plans 13 October 2015
Resources for Health Brokers Still a Question Mark as Open Enrollment Nears 17 September 2015
CMS Memo Points to More Regulatory Intervention in Network Adequacy, Mike Adelberg Says 11 September 2015

more media mentions »

Contact



David R. Zook, Washington, D.C.
+1 202 589 2809
DISCLAIMER

Transmission of information to us via this feature does not establish a privileged relationship. Do not send any information that you would have treated confidentially.

Decline